A safety open-label study of Gevokizumab in the treatment of patients with chronic non-infectious Uveitis disease, an eXtension study. The EYEGUARD-X study.

Trial Profile

A safety open-label study of Gevokizumab in the treatment of patients with chronic non-infectious Uveitis disease, an eXtension study. The EYEGUARD-X study.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Gevokizumab (Primary)
  • Indications Uveitis
  • Focus Adverse reactions; Registrational
  • Acronyms EYEGUARD-X
  • Sponsors Servier
  • Most Recent Events

    • 21 Oct 2015 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
    • 12 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top